Mining Gene Expression Data of Multiple Sclerosis
暂无分享,去创建一个
Ke Li | Zhenli Zhu | Qin Zhang | Ke Li | P. Guo | Pi Guo | Qin Zhang | Zhengliang Huang | Zhenglian Huang | Zhenli Zhu
[1] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[2] Yong Qian,et al. Hybrid Models Identified a 12-Gene Signature for Lung Cancer Prognosis and Chemoresponse Prediction , 2010, PloS one.
[3] J. Lünemann,et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis , 2003, The Lancet.
[4] D. Altmann. Evaluating the evidence for multiple sclerosis as an autoimmune disease. , 2005, Archives of neurology.
[5] T. Speed,et al. Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.
[6] J. Satoh,et al. Microarray analysis identifies an aberrant expression of apoptosis and DNA damage-regulatory genes in multiple sclerosis , 2005, Neurobiology of Disease.
[7] Geoffrey J. McLachlan,et al. Analyzing Microarray Gene Expression Data , 2004 .
[8] J. Trent,et al. Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays , 1999 .
[9] W. F. Azevedo. MolDock applied to structure-based virtual screening. , 2010 .
[10] M. Schummer,et al. Selecting Differentially Expressed Genes from Microarray Experiments , 2003, Biometrics.
[11] W. F. de Azevedo,et al. Molecular model for the binary complex of uropepsin and pepstatin. , 2001, Biochemical and biophysical research communications.
[12] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[13] Frauke Zipp,et al. Neuronal Damage in Autoimmune Neuroinflammation Mediated by the Death Ligand TRAIL , 2005, Neuron.
[14] Zhi-Qin Xi,et al. HSPBAP1 is found extensively in the anterior temporal neocortex of patients with intractable epilepsy , 2007, Synapse.
[15] X H Zhou,et al. Building a disease risk model of osteoporosis based on traditional Chinese medicine symptoms and western medicine risk factors , 2012, Statistics in medicine.
[16] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[17] S H Kim,et al. Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[18] F. Canduri,et al. Molecular model of cyclin-dependent kinase 5 complexed with roscovitine. , 2002, Biochemical and biophysical research communications.
[19] S. Kikuchi,et al. TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis , 2005, Journal of Neuroimmunology.
[20] Jeffrey T. Chang,et al. GATHER: a systems approach to interpreting genomic signatures , 2006, Bioinform..
[21] Walter Filgueira de Azevedo. Structure-Based Virtual Screening , 2010 .
[22] T. Wienker,et al. Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis , 2004, Journal of Neuroimmunology.
[23] Ludwig Kappos,et al. Multiple sclerosis as a generalized CNS disease—comparative microarray analysis of normal appearing white matter and lesions in secondary progressive MS , 2004, Journal of Neuroimmunology.
[24] Aixia Guo,et al. Gene Selection for Cancer Classification using Support Vector Machines , 2014 .
[25] W. L. Benedict,et al. Multiple Sclerosis , 2007, Journal - Michigan State Medical Society.
[26] M. Buttmann,et al. TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-β treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response , 2007, Journal of Neuroimmunology.
[27] M. Ramanathan,et al. Interferon-beta modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients. , 2006, Multiple sclerosis.
[28] A. Brinkmann,et al. Structure and function of GC79/TRPS1, a novel androgen-repressible apoptosis gene , 2002, Apoptosis.
[29] C A Smith,et al. Identification and characterization of a new member of the TNF family that induces apoptosis. , 1995, Immunity.
[30] M. Ramanathan,et al. Interferon-β modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients , 2006 .
[31] W. F. de Azevedo,et al. Bio-inspired algorithms applied to molecular docking simulations. , 2011, Current medicinal chemistry.
[32] W. F. de Azevedo,et al. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. , 2002, Biochemical and biophysical research communications.
[33] Stan Szpakowicz,et al. Beyond Accuracy, F-Score and ROC: A Family of Discriminant Measures for Performance Evaluation , 2006, Australian Conference on Artificial Intelligence.
[34] Jan Hillert,et al. Gene expression profiling in multiple sclerosis: A disease of the central nervous system, but with relapses triggered in the periphery? , 2010, Neurobiology of Disease.
[35] M. Weller,et al. Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system. , 1999, Immunology today.
[36] J. Benito-León,et al. TRAIL/TRAIL Receptor System and Susceptibility to Multiple Sclerosis , 2011, PloS one.
[37] S H Kim,et al. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. , 1997, European journal of biochemistry.
[38] Bianca Villavicencio,et al. Recent Progress of Molecular Docking Simulations Applied to Development of Drugs , 2012 .
[39] W. Xie,et al. Two human cDNAs, including a homolog of Arabidopsis FUS6 (COP11), suppress G-protein- and mitogen-activated protein kinase-mediated signal transduction in yeast and mammalian cells , 1996, Molecular and cellular biology.
[40] Javed Khan,et al. Gene expression profile in multiple sclerosis patients and healthy controls: identifying pathways relevant to disease. , 2003, Human molecular genetics.
[41] W. F. de Azevedo,et al. Structure of human uropepsin at 2.45 A resolution. , 2001, Acta crystallographica. Section D, Biological crystallography.
[42] Donna K. Slonim,et al. Getting Started in Gene Expression Microarray Analysis , 2009, PLoS Comput. Biol..
[43] Witold R. Rudnicki,et al. Feature Selection with the Boruta Package , 2010 .
[44] W. F. de Azevedo. MolDock applied to structure-based virtual screening. , 2010, Current drug targets.